NEW YORK – The Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office on Wednesday invalidated Exact Sciences' US Patent No. 11,634,781, which covers a central component of the company's Cologuard colorectal cancer screening assay.

纽约——美国专利商标局的专利审判和上诉委员会（PTAB）周三宣布，Exact Sciences公司的美国专利号11,634,781无效，该专利涵盖了该公司Cologuard结直肠癌筛查检测的一个核心组件。

The PTAB's final decision, which found all 20 claims of the '781 patent unpatentable, ends an

PTAB的最终决定认为'781专利的所有20项权利要求都不符合专利条件，该决定结束了

inter partes

双方之间

review of the patent that

专利的审查

Geneoscopy had requested

Geneoscopy 曾请求

last year as part of an ongoing lawsuit between the two companies.

去年，作为这两家公司之间持续诉讼的一部分。

Exact Sciences

精准科学

initially sued Geneoscopy

最初起诉了Geneoscopy

in 2023, alleging that Geneoscopy's ColoSense colorectal cancer screening test infringes its '781 patent.

2023年，指控Geneoscopy的ColoSense结直肠癌筛查测试侵犯其'781专利。

Geneoscopy countersued

基因镜公司反诉

the following year, prompting Exact Sciences to request a preliminary injunction against Geneoscopy.

次年，促使Exact Sciences公司要求对Geneoscopy发布初步禁令。

In the court filing, the PTAB wrote that Geneoscopy had shown 'by a preponderance of evidence' that the claims made in the '781 patent are unpatentable because they are obvious in light of prior art related to stool sample collection and processing.

在法庭文件中，PTAB写道，Geneoscopy已经通过“证据优势”表明，“781专利”中的主张是不可申请专利的，因为根据与粪便样本收集和处理相关的现有技术，这些主张是显而易见的。

The PTAB has also initiated an

PTAB 还启动了

inter partes

双方之间

review of another patent held by Exact Sciences and challenged by Geneoscopy. This patent, US Patent No. 11,970,746, pertains to methods of stool sample processing and analysis related to fecal occult blood testing.

Geneoscopy 对 Exact Sciences 持有的另一项专利提出的挑战的审查。该专利，美国专利号 11,970,746，涉及与粪便隐血试验相关的粪便样本处理和分析方法。

Geneoscopy's US Food and Drug Administration-approved ColoSense test detects RNA associated with colorectal cancer as well as occult hemoglobin in stool.

Geneoscopy公司获得美国食品药品监督管理局批准的ColoSense测试，可检测与结直肠癌相关的RNA以及粪便中的隐血血红蛋白。

'The PTAB's final decision validates what we have believed all along — that the claims in the '781 patent should never have been issued,' Andrew Barnell, CEO and cofounder of Geneoscopy, said in a statement. 'This outcome not only reinforces the strength of our position but helps ensure that invalid patents cannot be used to limit patient access to life-saving colorectal cancer screening options like ColoSense.'.

“PTAB的最终决定证实了我们一直以来的看法——'781专利的主张本就不应被批准，”Geneoscopy首席执行官兼联合创始人安德鲁·巴内尔在一份声明中说道。“这一结果不仅巩固了我们的立场，还有助于确保无效专利不会被用来限制患者获取诸如ColoSense这样的挽救生命的结直肠癌筛查选项。”

'While we have tremendous respect for the United States Patent and Trademark Office, we disagree with the decision and are evaluating all available options in response,' a spokesperson for Exact Sciences said in an email. 'We will continue to vigorously pursue our patent infringement and false advertising claims against Geneoscopy in federal district court.'.

“虽然我们非常尊重美国专利商标局，但我们不同意这一决定，并正在评估所有可用的应对选项，”精密科学公司的发言人在电子邮件中表示。“我们将继续在联邦地区法院大力追究针对Geneoscopy的专利侵权和虚假广告指控。”